Recipharm designates Germany site as Centre of Excellence
Charlie Blackie-Kelly | October 9, 2025 | News story | Research and Development | CDMO, Cuxhaven, Recipharm, biologics
Recipharm has designated its Cuxhaven, Germany facility as the company’s Centre of Excellence for Advanced Biologics Analytical Services.
The multi-product facility recently underwent significant renovations that included the addition of purpose-built, state-of-the-art Current Good Manufacturing Practices (CGMP) analytical laboratories.
The site now provides a comprehensive range of advanced analytical testing services for both drug substance and drug product, including microbiological and viral assay validation, nucleic acid quantification, and complex analytical techniques such as ddPCR, qPCR and Western blotting.
According to Recipharm, while the Cuxhaven site already supports projects from early development through to commercial manufacturing, the expansion of its analytical capabilities establishes it as a key hub for developing advanced modalities – including advanced therapy medicinal products (ATMPs) and biologics – leading to its designation as a Centre of Excellence.
Vikas Gupta, president of Recipharm Advanced Bio segment, said: “By adding key analytical services in Cuxhaven, we are reducing our reliance on external third-party labs, and providing our customers with faster, more cost-effective access to the highest quality analytical testing.”
Recipharm is a global contract development and manufacturing organisation (CDMO) with operations across France, Germany, India, Italy, Portugal, Spain, Sweden and the United States. Its Advanced Bio division, partly based at the Cuxhaven site, focuses on the development and commercialisation of ATMPs from pre-clinical through to early development stages.
Related Content
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a …
